Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Inflammatory Bowel Diseases

Free Subscription Articles published in PLoS One Retrieve available abstracts of 108 articles: HTML format

Single Articles

January 2025
1. LEE H, Ko DS, Heo HJ, Baek SE, et al
   Uncovering NK cell sabotage in gut diseases via single cell transcriptomics.
   PLoS One. 2025;20:e0315981.
   PubMed     Abstract available
   
   
   
2. ZUO Y, Li M, Cao J, Wang J, et al
   Assessment tools for transition readiness in adolescents with inflammatory bowel disease: A scoping review.
   PLoS One. 2025;20:e0317109.
   PubMed     Abstract available
   
   
   
3. S DSN, Sundararajan V
   Gene expression analysis reveals mir-29 as a linker regulatory molecule among rheumatoid arthritis, inflammatory bowel disease, and dementia: Insights from systems biology approach.
   PLoS One. 2025;20:e0316584.
   PubMed     Abstract available
   
   
   
4. SARTAIN S, Al-Ezairej M, McDonnell M, Westoby C, et al
   Iron deficiency and fatigue in inflammatory bowel disease: A systematic review.
   PLoS One. 2025;20:e0304293.
   PubMed     Abstract available
   
   
   
5. WEDENOJA S, Ritari J, Partanen J, Kere J, et al
   Enrichment of rare CFTR variants in Finnish patients with congenital chloride diarrhea.
   PLoS One. 2025;20:e0318249.
   PubMed     Abstract available
   
   
   
6. LUO L, Tang X, Xu J, Bao Y, et al
   The causal effects of inflammatory bowel disease on its ocular manifestations: A Mendelian randomization study.
   PLoS One. 2025;20:e0316437.
   PubMed     Abstract available
   
   
   
7. SINCLAIR J, Brooks-Warburton J, Baker L, Pujari AN, et al
   Vibrational exercise for Crohn's to observe response (VECTOR): Protocol for a randomized controlled trial.
   PLoS One. 2025;20:e0319685.
   PubMed     Abstract available
   
   
   
8. LI L, Chen X, Li T, Sun B, et al
   Integrated analysis and single-cell sequencing of mitochondrial metabolism related gene molecular subtype and diagnostic model in ulcerative colitis.
   PLoS One. 2025;20:e0320010.
   PubMed     Abstract available
   
   
   
9. HUANG H, Li P, Vernon-Roberts A, Day AS, et al
   The Inflammatory Bowel Disease Knowledge Inventory Device 2 (IBD-KID2) is an effective tool for measuring disease-specific knowledge in Chinese patients.
   PLoS One. 2025;20:e0321036.
   PubMed     Abstract available
   
   
   
10. LEE J, Kim B
    Zero inflated high dimensional compositional data with DeepInsight.
    PLoS One. 2025;20:e0320832.
    PubMed     Abstract available
    
    
    
11. GHYSELINCK J, Verstrepen L, Rakebrandt M, Marynissen S, et al
    In vitro fermentation of yeast cell walls (mannan-oligosaccharide) and purified beta-glucans modulates the colonic microbiota of dogs with inflammatory bowel disease and demonstrates protective effects on barrier integrity and anti-inflammatory proper
    PLoS One. 2025;20:e0322877.
    PubMed     Abstract available
    
    
    
12. 
    Correction: Development of a novel complex inflammatory bowel disease mouse model: Reproducing human inflammatory bowel disease etiologies in mice.
    PLoS One. 2025;20:e0324178.
    PubMed     Abstract available
    
    
    
13. WANG W, Wen Y, Luo J, Miao Y, et al
    Heat shock transcription factor 2 reduces mitochondrial pathway apoptosis in intestinal epithelial cells by inhibiting the increase in mitochondrial membrane permeability in ulcerative colitis.
    PLoS One. 2025;20:e0325275.
    PubMed     Abstract available
    
    
    
14. SAETERSTAD S, Ostvik AE, Royset ES, Bakke I, et al
    Correction: Profound gene expression changes in the epithelial monolayer of active ulcerative colitis and Crohn's disease.
    PLoS One. 2025;20:e0325481.
    PubMed     Abstract available
    
    
    
15. YUAN J, Gao C, Xin W, Meng F, et al
    Screening and validation of 3'-Methoxydaidzein as a therapeutic agent in ulcerative colitis based on disulfidptosis-associated molecular clusters.
    PLoS One. 2025;20:e0324586.
    PubMed     Abstract available
    
    
    
16. TEKIN L, Genc D
    CCR2 overexpressing gingiva mesenchymal stem cells provide high intestinal regeneration in a rat model of ulcerative colitis.
    PLoS One. 2025;20:e0325566.
    PubMed     Abstract available
    
    
    
17. LIU N, Hou Y, Yu M, Liu G, et al
    Identification of novel drug targets through integrative PWAS of brain and plasma proteins with Ulcerative Colitis GWAS.
    PLoS One. 2025;20:e0324035.
    PubMed     Abstract available
    
    
    
18. LIU T, Zhang X, Chen R, Sun Y, et al
    Uncovering common disease mechanisms and critical biomarkers in Crohn's disease with concurrent psoriasis and exploring potential therapeutic agents.
    PLoS One. 2025;20:e0324007.
    PubMed     Abstract available
    
    
    
19. CHEN P, She Y, Wang L, Li Y, et al
    Outcomes of medical and surgical treatment for intestinal fistulizing Crohn's disease.
    PLoS One. 2025;20:e0327784.
    PubMed     Abstract available
    
    
    
20. ZHANG F, Jiang X, Chen X, Wang Z, et al
    Identification of differentially expressed genes associated with ferroptosis in ulcerative colitis.
    PLoS One. 2025;20:e0327990.
    PubMed     Abstract available
    
    
    
21. LIU LF, Fan YW, Lv Y, Liu ZX, et al
    Strategies for assessing and preventing cardiovascular disease risk in inflammatory bowel disease patients: A meta-analysis and meta-regression and bibliometric review.
    PLoS One. 2025;20:e0327734.
    PubMed     Abstract available
    
    
    
22. TANG Q, Tang X, Yin W, Li Y, et al
    Infective pneumonia following the use of tumor necrosis factor-alpha inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
    PLoS One. 2025;20:e0317242.
    PubMed     Abstract available
    
    
    
23. SECO-CERVERA M, Gisbert-Ferrandiz L, Macias-Ceja DC, Ortiz-Masia D, et al
    Down-regulation of MIR-378A-3P expression associated with inflammation: The effects of restoring its levels.
    PLoS One. 2025;20:e0329685.
    PubMed     Abstract available
    
    
    
24. KUZDAS-SALLABERGER M, Steininger B, Stohr D, Mustak-Blagusz M, et al
    Changes in patient-reported outcomes (PROs) and fecal calprotectin levels in patients with inflammatory bowel disease following a three-week gastrointestinal inpatient rehabilitation.
    PLoS One. 2025;20:e0330922.
    PubMed     Abstract available
    
    
    
25. DEMERS K, Hendrix EMB, Ardabili AR, Bredero QM, et al
    Lifestyle and psychosocial factors in inflammatory bowel disease: Prevalence, impact, motivation, and support needs.
    PLoS One. 2025;20:e0331092.
    PubMed     Abstract available
    
    
    
26. VERAL MA, Pickup RW, Roy M, Sanderson J, et al
    Geographic distribution of inflammatory bowel disease in the UK: A spatially explicit survey.
    PLoS One. 2025;20:e0329317.
    PubMed     Abstract available
    
    
    
27. MISAGHIAN S, Jafri MS
    Transcriptional profiling identification of inflammatory signaling pathways in ulcerative colitis.
    PLoS One. 2025;20:e0330332.
    PubMed     Abstract available
    
    
    
28. ZHAO J, Miao D, Xiao T, Yang T, et al
    Global disease burden of inflammatory bowel disease in women and women of childbearing age from 1990 to 2021 and its prediction to 2040.
    PLoS One. 2025;20:e0331034.
    PubMed     Abstract available
    
    
    
29. CAI B, Qin X, Huang X, He X, et al
    Molecular mechanisms of dragon's blood in treating ulcerative colitis based on NF-kappab/NLPR3/Caspase-1 pyroptosis signaling pathway.
    PLoS One. 2025;20:e0331570.
    PubMed     Abstract available
    
    
    
30. XIA P, Deng F, Liu D
    Development and validation of a machine learning-based predictive model for clinical remission in Crohn's disease patients receiving Adalimumab therapy.
    PLoS One. 2025;20:e0331447.
    PubMed     Abstract available
    
    
    
31. ALEM M, Abtahi Froushani SM, Hajighahramani N, Hosseini-Asl S, et al
    Immuno-informatics voyage through molecular mimicry of Heat Shock Proteins: Potential IBD immunopathogenesis.
    PLoS One. 2025;20:e0333618.
    PubMed     Abstract available
    
    
    
32. SHEN P, Xiong H, Luo QH, Ding YF, et al
    Investigating the common genetic basis between inflammatory bowel disease and metabolic syndrome through genomic structural equation modeling.
    PLoS One. 2025;20:e0334456.
    PubMed     Abstract available
    
    
    January 2024
33. ISHIDA N, Takahashi K, Asai Y, Miyazu T, et al
    Albumin change predicts failure in ulcerative colitis treated with adalimumab.
    PLoS One. 2024;19:e0295681.
    PubMed     Abstract available
    
    
    
34. QIAN Z, Zhang M, Lu T, Yu J, et al
    Propolis alleviates ulcerative colitis injury by inhibiting the protein kinase C - transient receptor potential cation channel subfamily V member 1 - calcitonin gene-related peptide/substance P (PKC-TRPV1-CGRP/SP) signaling axis.
    PLoS One. 2024;19:e0294169.
    PubMed     Abstract available
    
    
    
35. SCHNITZLER F, Tillack-Schreiber C, Szokodi D, Braun I, et al
    Safety of perioperative treatment with biologics in patients with inflammatory bowel disease undergoing bowel surgery: Experience from a large urban center.
    PLoS One. 2024;19:e0290887.
    PubMed     Abstract available
    
    
    
36. KATHER S, Kacza J, Pfannkuche H, Bottcher D, et al
    Expression of the cobalamin transporters cubam and MRP1 in the canine ileum-Upregulation in chronic inflammatory enteropathy.
    PLoS One. 2024;19:e0296024.
    PubMed     Abstract available
    
    
    
37. LLUANSI A, Lliros M, Carreras-Torres R, Bahi A, et al
    Impact of bread diet on intestinal dysbiosis and irritable bowel syndrome symptoms in quiescent ulcerative colitis: A pilot study.
    PLoS One. 2024;19:e0297836.
    PubMed     Abstract available
    
    
    
38. JAMES JP, Riis LB, Sokilde R, Malham M, et al
    Short noncoding RNAs as predictive biomarkers for the development from inflammatory bowel disease unclassified to Crohn's disease or ulcerative colitis.
    PLoS One. 2024;19:e0297353.
    PubMed     Abstract available
    
    
    
39. FU C, Wang Q, Chen Y, Zhang Y, et al
    Exploring the causal relationship between airborne particulate matter and ulcerative colitis: A two-sample mendelian randomization study.
    PLoS One. 2024;19:e0300066.
    PubMed     Abstract available
    
    
    
40. RIDSDALE K, Khurana K, Taslim AT, Robinson JK, et al
    Quality improvement exercises in Inflammatory Bowel Disease (IBD) services: A scoping review.
    PLoS One. 2024;19:e0298374.
    PubMed     Abstract available
    
    
    
41. WANG Z, Nie J, Song X, Denson LA, et al
    A comparison of Bayesian and frequentist approaches to incorporating clinical and biological information for the prediction of response to standardized pediatric colitis therapy.
    PLoS One. 2024;19:e0295814.
    PubMed     Abstract available
    
    
    
42. CHEN K, Zhang S, Cui G, Zhang X, et al
    Establishment of a hybrid model of atherosclerosis and acute colitis in ApoE-/- mice.
    PLoS One. 2024;19:e0289820.
    PubMed     Abstract available
    
    
    
43. SALDOVA R, Thomsson KA, Wilkinson H, Chatterjee M, et al
    Characterization of intestinal O-glycome in reactive oxygen species deficiency.
    PLoS One. 2024;19:e0297292.
    PubMed     Abstract available
    
    
    
44. OCAMPO YC, Castro JP, Pajaro IB, Caro D, et al
    Protective effect of sucrose esters from cape gooseberry (Physalis peruviana L.) in TNBS-induced colitis.
    PLoS One. 2024;19:e0299687.
    PubMed     Abstract available
    
    
    
45. TORRES-HUERTA A, Ruley-Haase K, Reed T, Boger-May A, et al
    Retinoid orphan receptor gamma t (rorgammat) promotes inflammatory eosinophilia but is dispensable for innate immune-mediated colitis.
    PLoS One. 2024;19:e0300892.
    PubMed     Abstract available
    
    
    
46. SINCLAIR J, Brooks-Warburton J, Bottoms L
    Perceptions, behaviours and barriers towards exercise practices in inflammatory bowel disease.
    PLoS One. 2024;19:e0299228.
    PubMed     Abstract available
    
    
    
47. QUENEHERVE L, Trang-Poisson C, Fantou A, Flamant M, et al
    Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
    PLoS One. 2024;19:e0298313.
    PubMed     Abstract available
    
    
    
48. HU J, Huang Y, Jia R, Wang X, et al
    Absolute monocyte counts could predict disease activity and secondary loss of response of patients with Crohn's disease treated with anti-TNF-alpha drug.
    PLoS One. 2024;19:e0301797.
    PubMed     Abstract available
    
    
    
49. FU W, Zhu B, Chen J, Jin X, et al
    Risk relationship between inflammatory bowel disease and urolithiasis: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0301545.
    PubMed     Abstract available
    
    
    
50. WU H, Jiang F, Yuan W, Zhao Y, et al
    Rauwolfia polysaccharide can inhibit the progress of ulcerative colitis through NOS2-mediated JAK2/STAT3 pathway.
    PLoS One. 2024;19:e0301660.
    PubMed     Abstract available
    
    
    
51. XU F, Carlson SA, Greenlund KJ
    Understanding primary care providers' attitudes towards preventive screenings to patients with inflammatory bowel disease.
    PLoS One. 2024;19:e0299890.
    PubMed     Abstract available
    
    
    
52. ALAHDAL H, Almuneef G, Alkhulaifi MM, Aldibasi O, et al
    Gut microbiota composition in patients with Crohn's disease in Saudi Arabia.
    PLoS One. 2024;19:e0299749.
    PubMed     Abstract available
    
    
    
53. KODAMA M, Okano S, Nojri S, Abe K, et al
    Longitudinal and regional association between dietary factors and prevalence of Crohn's disease in Japan.
    PLoS One. 2024;19:e0300580.
    PubMed     Abstract available
    
    
    
54. WANG X, Li T, Chen Q
    Causal relationship between ulcerative colitis and male infertility: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0303827.
    PubMed     Abstract available
    
    
    
55. RANA T, Korolkova OY, Rachakonda G, Williams AD, et al
    Correction: Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease.
    PLoS One. 2024;19:e0304732.
    PubMed     Abstract available
    
    
    
56. 
    Sources of diagnostic delay for people with Crohn's disease and ulcerative colitis: Qualitative research study.
    PLoS One. 2024;19:e0301672.
    PubMed     Abstract available
    
    
    
57. LI L, Zhang M, Gu M, Li J, et al
    The causal relationship between autoimmune diseases and age-related macular degeneration: A two-sample mendelian randomization study.
    PLoS One. 2024;19:e0303170.
    PubMed     Abstract available
    
    
    
58. CHI G, Pei J, Li X
    Inflammatory bowel disease and risk of autoimmune hepatitis: A univariable and multivariable Mendelian randomization study.
    PLoS One. 2024;19:e0305220.
    PubMed     Abstract available
    
    
    
59. ZHANG K, Nakaoka S
    An energy landscape approach reveals the potential key bacteria contributing to the development of inflammatory bowel disease.
    PLoS One. 2024;19:e0302151.
    PubMed     Abstract available
    
    
    
60. WANG N, Li Z, Cao L, Cui Z, et al
    Trilobatin ameliorates dextran sulfate sodium-induced ulcerative colitis in mice via the NF-kappaB pathway and alterations in gut microbiota.
    PLoS One. 2024;19:e0305926.
    PubMed     Abstract available
    
    
    
61. KHANMOHAMMADI S, Sheidaei A, Alatab S, Tabatabaei-Malazy O, et al
    Sex and age differences in inflammatory bowel disease patients; a nationwide study based on Iranian Registry of Crohn's and Colitis (IRCC).
    PLoS One. 2024;19:e0304792.
    PubMed     Abstract available
    
    
    
62. JONES K, Kimble R, Baker K, Tew GA, et al
    Correction: Effects of structured exercise programmes on physiological and psychological outcomes in adults with inflammatory bowel disease (IBD): A systematic review and meta-analysis.
    PLoS One. 2024;19:e0307509.
    PubMed     Abstract available
    
    
    
63. HOTEIT M, Ftouni N, Olayan M, Hallit S, et al
    Self-reported food intolerance, dietary supplement use and malnutrition in chronic inflammatory bowel diseases: Findings from a cross-sectional study in Lebanon.
    PLoS One. 2024;19:e0305352.
    PubMed     Abstract available
    
    
    
64. OLSON JL, Castillo G, Palumbo A, Harrison M, et al
    A qualitative evaluation of treatment fidelity alongside a pilot trial of a novel therapy for pediatric Inflammatory Bowel Disease.
    PLoS One. 2024;19:e0292709.
    PubMed     Abstract available
    
    
    
65. CRISI PE, Giordano MV, Luciani A, Gramenzi A, et al
    Evaluation of the fatty acid-based erythrocyte membrane lipidome in cats with food responsive enteropathy, inflammatory bowel disease and low-grade intestinal T-cell lymphoma.
    PLoS One. 2024;19:e0307757.
    PubMed     Abstract available
    
    
    
66. KOSHIBA R, Kakimoto K, Mizuta N, Numa K, et al
    C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis.
    PLoS One. 2024;19:e0305324.
    PubMed     Abstract available
    
    
    
67. LI J, Zhang C, Xu Y, Yang L, et al
    Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0309144.
    PubMed     Abstract available
    
    
    
68. PUSA T, Rousu J
    Stable biomarker discovery in multi-omics data via canonical correlation analysis.
    PLoS One. 2024;19:e0309921.
    PubMed     Abstract available
    
    
    
69. KUENSTNER JT, Zhang P, Potula R, Galarneau JM, et al
    Human antibodies against Mycobacterium avium ssp. paratuberculosis combined with cytokine levels for the diagnosis and selection of Crohn's disease patients for anti-mycobacterial therapy-A pilot study.
    PLoS One. 2024;19:e0308911.
    PubMed     Abstract available
    
    
    
70. JIANG T, Cai Z, Liu C, Zhang B, et al
    Pharmacological treatment of postoperative recurrence of Crohn's disease: Protocol for systematic review and network meta-analysis.
    PLoS One. 2024;19:e0310752.
    PubMed     Abstract available
    
    
    
71. ZHANG Y, Ma Z, Kang L, Yang L, et al
    Effect of telomere shortening on disease progression in patients with inflammatory bowel disease: A systematic review and meta-analysis protocol.
    PLoS One. 2024;19:e0311662.
    PubMed     Abstract available
    
    
    
72. BUGDA GWILT K, Thiagarajah JR
    Overcoming problematic growth phenotypes in organoids from patients with monogenic GI disease.
    PLoS One. 2024;19:e0309072.
    PubMed     Abstract available
    
    
    
73. SCHLEE C, Uecker C, Oznur O, Bauer N, et al
    Participants' perspectives on a multimodal stress management and comprehensive lifestyle modification program for patients with Crohn's disease-A qualitative interview study.
    PLoS One. 2024;19:e0313127.
    PubMed     Abstract available
    
    
    
74. ALKHATIB NS, Almutairi AR, Almadi M, Halloush S, et al
    Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.
    PLoS One. 2024;19:e0312603.
    PubMed     Abstract available
    
    
    
75. SEO SM, Kim NW, Yoo ES, Lee JH, et al
    Development of a novel complex inflammatory bowel disease mouse model: Reproducing human inflammatory bowel disease etiologies in mice.
    PLoS One. 2024;19:e0311310.
    PubMed     Abstract available
    
    
    
76. GUO B, Li H, Cui Q, Li J, et al
    Translation, cross-cultural adaptation and validation of the Chinese version of the IBD-Control questionnaire: A patient-reported outcome measure in inflammatory bowel disease.
    PLoS One. 2024;19:e0311529.
    PubMed     Abstract available
    
    
    
77. CARLSEN K, Thingholm LB, Dempfle A, Malham M, et al
    Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.
    PLoS One. 2024;19:e0311604.
    PubMed     Abstract available
    
    
    
78. LU Y, Su Y, Wang N, Li D, et al
    Identification of O-glycosylation related genes and subtypes in ulcerative colitis based on machine learning.
    PLoS One. 2024;19:e0311495.
    PubMed     Abstract available
    
    
    
79. NODA T, Kuwaki K, Machida M, Okumura Y, et al
    Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study.
    PLoS One. 2024;19:e0316181.
    PubMed     Abstract available
    
    
    January 2023
80. RUDRAPATNA VA, Cheng YW, Feuille C, Mosenia A, et al
    Creation of an ustekinumab external control arm for Crohn's disease using electronic health records data: A pilot study.
    PLoS One. 2023;18:e0282267.
    PubMed     Abstract available
    
    
    
81. ZONG W, Patel A, Chang V, Mitchel EB, et al
    Clinical and lifestyle patterns in Asian children with inflammatory bowel disease in the U.S.
    PLoS One. 2023;18:e0281949.
    PubMed     Abstract available
    
    
    
82. SCHORLING E, Lick S, Steinberg P, Bruggemann DA, et al
    Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis.
    PLoS One. 2023;18:e0283865.
    PubMed     Abstract available
    
    
    
83. TANI M, Shinzaki S, Asakura A, Tashiro T, et al
    Seasonal variations in gut microbiota and disease course in patients with inflammatory bowel disease.
    PLoS One. 2023;18:e0283880.
    PubMed     Abstract available
    
    
    
84. HASAN N, Yang H
    Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models.
    PLoS One. 2023;18:e0285613.
    PubMed     Abstract available
    
    
    
85. ICHIMIYA T, Kazama T, Ishigami K, Yokoyama Y, et al
    Application of plasma alternative to serum for measuring leucine-rich alpha2-glycoprotein as a biomarker of inflammatory bowel disease.
    PLoS One. 2023;18:e0286415.
    PubMed     Abstract available
    
    
    
86. DONG F, Kern I, Weidner J, Kugler K, et al
    Clinical course of new-onset Crohn's disease in children and adolescents in dependency of age, initial location, initial severity level and therapy over the period 2000-2014 based on the Saxon Pediatric IBD-Registry in Germany.
    PLoS One. 2023;18:e0287860.
    PubMed     Abstract available
    
    
    
87. NAGAHORI M, Imai T, Nakashoji M, Tairaka A, et al
    A web-based survey on self-management for patients with inflammatory bowel disease in Japan.
    PLoS One. 2023;18:e0287618.
    PubMed     Abstract available
    
    
    
88. HATAMNEJAD MR, Shirvani M, Pourhoseingholi MA, Balaii H, et al
    Translation and cross-cultural adaptation of the Persian version of inflammatory bowel disease-fatigue (IBD-F) self-assessment questionnaire.
    PLoS One. 2023;18:e0288592.
    PubMed     Abstract available
    
    
    
89. PATRA R, Dey AK, Mukherjee S
    Identification of genes critical for inducing ulcerative colitis and exploring their tumorigenic potential in human colorectal carcinoma.
    PLoS One. 2023;18:e0289064.
    PubMed     Abstract available
    
    
    
90. LIN A, Tan Y, Chen J, Liu X, et al
    Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis.
    PLoS One. 2023;18:e0289021.
    PubMed     Abstract available
    
    
    
91. OTAKE-KASAMOTO Y, Shinzaki S, Hiyama S, Tashiro T, et al
    Carbon dioxide insufflation reduces the relapse of ulcerative colitis after colonoscopy: A randomized controlled trial.
    PLoS One. 2023;18:e0290329.
    PubMed     Abstract available
    
    
    
92. LIU Y, Zhang YZ, Imoto S
    Microbial Gene Ontology informed deep neural network for microbe functionality discovery in human diseases.
    PLoS One. 2023;18:e0290307.
    PubMed     Abstract available
    
    
    
93. MEUNIER M, Spillmann A, Rousseaux C, Schwamborn K, et al
    An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease.
    PLoS One. 2023;18:e0283489.
    PubMed     Abstract available
    
    
    
94. KAZAMA T, Ando K, Ueno N, Fujiya M, et al
    Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study.
    PLoS One. 2023;18:e0288393.
    PubMed     Abstract available
    
    
    
95. SAKOWITZ S, Bakhtiyar SS, Mallick S, Khoraminejad B, et al
    Decreasing rates of colectomy for benign neoplasms: A nationwide analysis.
    PLoS One. 2023;18:e0293389.
    PubMed     Abstract available
    
    
    
96. CHAE K, Seo YS, Yu YM, Chang MJ, et al
    An indirect comparison of efficacy including histologic assessment and safety in biologic therapy in ulcerative colitis: Systemic review and network meta-analysis.
    PLoS One. 2023;18:e0293655.
    PubMed     Abstract available
    
    
    
97. OTT A, Tutdibi E, Goedicke-Fritz S, Schope J, et al
    Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease.
    PLoS One. 2023;18:e0288147.
    PubMed     Abstract available
    
    
    
98. KONECNY AJ, Shows DM, Lord JD
    Colonic mucosal associated invariant T cells in Crohn's disease have a diverse and non-public T cell receptor beta chain repertoire.
    PLoS One. 2023;18:e0285918.
    PubMed     Abstract available
    
    
    
99. WASSERBAUER M, Mala S, Stechova K, Hlava S, et al
    Dysfunction of peripheral somatic and autonomic nervous system in patients with severe forms of Crohn's disease on biological therapy with TNFalpha inhibitors-A single center study.
    PLoS One. 2023;18:e0294441.
    PubMed     Abstract available
    
    
    
100. BAR O, Sudhof LS, Yockey LJ, Bergerat A, et al
     Comparison of vaginal microbiota between women with inflammatory bowel disease and healthy controls.
     PLoS One. 2023;18:e0284709.
     PubMed     Abstract available
     
     
     
101. YIN T, Ye R, Wang Q, Wang L, et al
     Difficulties in eating out of home while diagnosed with inflammatory bowel disease: A qualitative interview study from China.
     PLoS One. 2023;18:e0288908.
     PubMed     Abstract available
     
     
     
102. TATARU C, Livni M, Marean-Reardon C, Franco MC, et al
     Cytokine induced inflammatory bowel disease model using organ-on-a-chip technology.
     PLoS One. 2023;18:e0289314.
     PubMed     Abstract available
     
     
     
103. SUN W, Li E, Mao X, Zhang Y, et al
     The oligosaccharides of Xiasangju alleviates dextran sulfate sodium-induced colitis in mice by inhibiting inflammation.
     PLoS One. 2023;18:e0295324.
     PubMed     Abstract available
     
     
     
104. PACHECO M, Sa P, Santos G, Boa-Sorte N, et al
     Impact of an intervention program on drug adherence in patients with ulcerative colitis: Randomized clinical trial.
     PLoS One. 2023;18:e0295832.
     PubMed     Abstract available
     
     
     
105. SARDARI A, Usefi H
     Machine learning-based meta-analysis of colorectal cancer and inflammatory bowel disease.
     PLoS One. 2023;18:e0290192.
     PubMed     Abstract available
     
     
     
106. LEE YC, Kim TJ, Kim JH, Lee E, et al
     Short-term effects of ambient temperature on acute exacerbation of inflammatory bowel disease: A nationwide case-crossover study with external validation.
     PLoS One. 2023;18:e0291713.
     PubMed     Abstract available
     
     
     January 2021
107. ZHANG J, Wang XJ, Wu LJ, Yang L, et al
     Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway.
     PLoS One. 2021;16:e0252334.
     PubMed     Abstract available
     
     
     
108. SCHINEIS C, Ullrich A, Lehmann KS, Holmer C, et al
     Microscopic inflammation in ileocecal specimen does not correspond to a higher anastomotic leakage rate after ileocecal resection in Crohn's disease.
     PLoS One. 2021;16:e0247796.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.